Issues
-
Cover Image
Cover Image
About the Cover
Human papilloma virus (HPV) is associated with several malignancies, especially cervical and head and neck cancers. Vaccines are being used to treat various cancers, but with limited success. Atherton et al. demonstrate a promising approach that may provide more consistent antitumor responses. They infected mice with the oncolytic Maraba virus, which selectively infects and lyses tumor cells, while also acting as a vaccine, based on attenuated HPV E6 and E7 transforming proteins. Antigen-specific CD8+ T cells were activated, HPV+ tumors eradicated, and memory induced. This one-two punch strategy may overcome the immunosuppression of advanced disease. Read more in this issue starting on page 847. The micrograph is a hematoxylin-eosin stain of a TC1 tumor harvested from a vaccine-treated mouse. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
Highlights from the Literature
Priority Briefs
Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion
Research Articles
Customized Viral Immunotherapy for HPV-Associated Cancer
Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non–Small Cell Lung Cancer Patients
The Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells
Vaccine-activated CD8+ T cells that had weaker TCR signaling had stronger antitumor effects. Weak activation halted differentiation at the stem-like memory T-cell stage, generating more Tscm cells, and protected T effectors from antigen-induced exhaustion and apoptosis.
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.